New combo therapy shows promise for Hard-to-Treat breast cancer on chest wall

NCT ID NCT03095352

Completed Disease control Sponsor: Laura Huppert, MD, BA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug carboplatin works better than carboplatin alone for breast cancer that has returned on the chest wall. The trial included 76 people with either triple-negative or hormone-resistant breast cancer. The main goal was to see if the combination could control the disease for at least 18 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CHEST WALL DISEASE

Contacts and locations

Locations

Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
Indiana University/Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Pittsburgh Cancer Institute

Pittsburgh, Pennsylvania, 15232, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.